Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Original ArticlesChronic Kidney Disease
You have accessRestricted Access

The Duke Activity Status Index in Patients with Chronic Kidney Disease: A Reliability Study

Pietro Ravani, Brett Kilb, Harman Bedi, Sharon Groeneveld, Serdar Yilmaz, Stefan Mustata and Alberta Kidney Disease Network
CJASN April 2012, 7 (4) 573-580; DOI: https://doi.org/10.2215/CJN.07990811
Pietro Ravani
*Departments of Medicine and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brett Kilb
*Departments of Medicine and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harman Bedi
†Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharon Groeneveld
*Departments of Medicine and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Serdar Yilmaz
‡Surgery, Faculty of Medicine, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Mustata
*Departments of Medicine and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Summary

Background and objectives Exercise capacity is impaired at a younger age in CKD patients than in the general population. This study examined the reliability of the Duke Activity Status Index (DASI) questionnaire as a measure of exercise capacity in medically stable adults with stage 3–4 CKD (estimated GFR [eGFR], 15–59 ml/min per 1.73 m2).

Design, setting, participants, & measurements Peak oxygen uptake (̇o2peak), estimated from DASI responses and cardiopulmonary exercise test measurements, was obtained at baseline and 6 months in a derivation sample (n=23) and once in a validation sample (n=20). Bland–Altman analysis and linear mixed models were used to estimate bias, concordance correlation coefficients, and intraclass correlation coefficients as the proportion of the variance due to participant (intertest reliability) and method (test–retest reliability).

Results The two samples were homogeneous with respect to age (mean 60±14 years), eGFR (35.5±15 ml/min per 1.73 m2), male sex (53%), and diabetes (56%). Mean measured ̇o2peak was 16.5±4 ml/kg per min. The DASI questionnaire overestimated ̇o2peak by 4.3 ml/kg per min. Intertest reliability was 53% when eGFR was ≥35 ml/min per 1.73 m2 (median) and 60% when eGFR was <35 ml/min per 1.73 m2 (P<0.01). Test–retest reliability was 81% when eGFR was <35 ml/min per 1.73 m2 and 71% when eGFR was ≥35 ml/min per 1.73 m2 (P<0.01).

Conclusions The DASI questionnaire may be a reliable measure of exercise capacity in CKD patients, especially when eGFR is <35 ml/min per 1.73 m2. Larger prospective studies are needed to determine its prognostic value.

Introduction

The prevalence of CKD is increasing worldwide and is considered a public health priority in the United States (1). Patients with CKD have impaired exercise capacity (EC), commonly resulting in physical disability, reduced quality of life, and increased health care resource utilization (2). EC is defined as the maximal ability to perform aerobic work (̇o2peak), and is the fundamental physiologic determinant of the ability to perform common daily activities safely and independently (3–5).

Loss of functional independence occurs when ̇o2peak falls <15 ml/kg per min in women and 18 ml/kg per min in men, occurring typically by age 80–85 years in healthy individuals (6,7). Patients with stage 3–4 CKD (estimated GFR [eGFR], 15–59 ml/min per 1.73 m2) reach these thresholds 20 years earlier, contributing to the low rate of independent functioning seen in this patient population (8,9).

Reduced EC is associated with increased cardiovascular mortality in the general population (10) and in patients with CKD (11). Progressive deterioration of EC parallels eGFR decline (12) and may herald increased cardiovascular risk at any stage of CKD (13–15). At the initiation of dialysis, mortality rates increase when ̇o2peak is below a critical level of 17.5 ml/kg per min (16). However, exercise rehabilitation can trigger cardioprotective mechanisms (17–20), increase EC, and improve health-related quality of life (8).

Appropriate assessment of EC is essential for patient risk stratification and the implementation and evaluation of exercise rehabilitation programs. Direct measurement of ̇o2peak by the cardiopulmonary exercise test (CPET; reference standard test) is complex, costly, and physically demanding for patients, limiting its routine application in clinical practice (21). Simple questionnaires may be preferred for screening and classification purposes in medically stable ambulatory patients (22).

The Duke Activity Status Index (DASI) is a self-administered questionnaire designed to assess physical function and predict EC within an office setting (23), and has been validated in patients with chronic cardiac and respiratory conditions (24–26). Although the DASI questionnaire has been used in renal disease populations (12,27,28), reliability and validity studies are lacking in CKD patients. The aim of this study was to assess the reliability and validity of the DASI questionnaire as a predictor of EC in patients with CKD.

Materials and Methods

Study Design and Objectives

We conducted a cross-sectional analysis of the test–retest reliability and intertest reliability (validity) of the DASI questionnaire. Because the questionnaire was initially developed for use in cardiac disease, we sought to derive a correction factor for the conversion of the DASI raw score into ̇o2peak for use in patients with CKD. Therefore, a derivation cohort who performed both the DASI questionnaire and CPET at two time points, 6 months apart to minimize recall bias, provided a correction factor and test–retest reliability data. A validation cohort was used to verify the performance of the corrected DASI questionnaire versus the reference standard method CPET.

Participants

Medically stable adults with stage 3–4 CKD were recruited over 6 months from two outpatient nephrology clinics (predialysis and post-transplant) in the Calgary area of the Alberta Health Services (29). Patients were eligible for the study if their eGFR was ≥15 and <60 ml/min per 1.73 m2, according to Modification of Diet in Renal Disease formula (30). Patients were excluded if any of the following criteria for medical instability had occurred within the month before enrollment: acute cardiorespiratory disease, including acute coronary syndrome, congestive heart failure, or pneumonia; uncontrolled diabetes, with plasma glucose >20 mmol/L or <4 mmol/L on at least two occasions; uncontrolled hypertension with systolic BP > 180 mmHg or diastolic BP >110 mmHg on at least two occasions; persistent hyperkalemia, with K>5.5 mmol/L; or musculoskeletal abnormalities exacerbated by or precluding exercise. Individuals who met the inclusion criteria were invited to attend an information session before confirming their intent to participate. The University of Calgary Conjoint Health Research Ethics Board approved the study protocol and each participant gave written informed consent.

Outcome

The outcome of interest was the concordance (absolute agreement) between the ̇o2peak directly measured and its estimate obtained using the DASI questionnaire. Measures of agreement included both intertest reliability (between-method agreement/validity) and test–retest reliability (within-method agreement).

CPET and Direct-Measured ̇o2peak

A symptom-limited CPET was performed on a cycle ergometer (Ergoline 800; SensorMedics, Yorba Linda, CA) using a workload increment of 5–20 W/min to yield an 8- to 12-minute test (3). ̇o2peak was determined from direct gas analysis using a breath-by-breath system (Vmax; SensorMedics), which was calibrated before every test according to the manufacturer’s recommendations. BP and a 12-lead electrocardiogram were monitored during testing, and ratings of shortness of breath and leg discomfort were recorded every 2 minutes using the Borg 6-20 rating of perceived exertion scale (31). Participants were asked to maintain a pedaling speed of 50–70 rpm and were encouraged to give maximal effort. Standard indications for test termination were followed (3). All tests were performed in the morning, with medications taken as prescribed. The CPET technician was blinded to the DASI score. Results of the CPET were not disclosed to the study participants.

DASI-Estimated ̇o2peak

The DASI questionnaire (23) consists of 12 items pertaining to the patient’s perceived ability to perform daily activities (Supplemental Materials) and takes fewer than 10 minutes to complete. Weighted averages for each question are based on the known energy requirement of the activity (in metabolic equivalent units). Responses are summed to give a raw DASI score (from 0 to 58.2) used to estimate ̇o2peak in milliliters per kilogram per minute. The DASI questionnaire was mailed to study participants 1 week before their scheduled CPET, with instructions to complete the questionnaire 2 days before the CPET and bring it to their testing session. No teaching or familiarization with the questionnaire was required. The DASI score was not disclosed to the study participants.

Independent Variables

Data on clinical characteristics, CKD causes, documented diagnosis of diabetes or cardiovascular disease (i.e., cerebrovascular, peripheral or coronary artery disease, and heart failure), and history of hypertension were obtained from the CKD database (29), and were defined based on the diagnosis-related group classification and International Classification of Diseases, Ninth Revision. Laboratory data were extracted from the same database.

Statistical Analyses

Power and Sample Size.

From data on variance components from previous studies (8), we estimated that a sample of 20 participants, each receiving two measurements, was necessary to demonstrate a significant difference (two-sided P value of 0.05) of 5 units in the response variable by measurement method (within-cluster covariate) with power >85% (32).

Descriptive Analyses.

Data are expressed as mean ± SD or as frequencies, as appropriate. Correlation was studied estimating the interclass Pearson coefficient (precision; relative agreement) and the Lin concordance correlation coefficient (CCC; absolute agreement) between measured and estimated ̇o2peak values (validity). Unadjusted and stratified differences (bias) and 95% limits of agreement were estimated using the Bland–Altman method (i.e., overall and by presence and absence of comorbidities, sex, and categories of age and eGFR).

Regression Models.

Linear mixed models were used to estimate the adjusted intraclass correlation coefficient (ICC; adjusted measure of absolute agreement). These models were built on the patient identifier treated as a random factor (random intercept models) and the measurement method as a fixed predictor to estimate the “method effect” (bias). The above-listed independent variables were used to control for confounding, to test interaction effects and other random effects, and to allow heteroscedastic residuals. Model comparison was performed by using likelihood ratio tests and checking the information criteria. Measures of reliability (ICCs) were estimated under the assumption of equal or unequal reliability (homo- or heteroscedasticity of the random effects). Residual analyses were performed to check model validity. Analyses were performed using Stata 11.2 SE software (StataCorp, College Station, TX).

Results

Patient Characteristics

The study profile is shown in Figure 1. Eighty consecutive patients were approached and 60 patients attended the information sessions. Forty-three patients (predialysis CKD, n=26; transplant, n=17) agreed to participate. Participants who were eligible but did not consent (n=20) were similar to study participants in terms of age, sex, eGFR, and comorbidities. The first consecutive 23 enrolled patients completed both the DASI questionnaire and CPET at baseline and at 6 months for test–retest reliability analysis (derivation sample). The subsequent 20 patients completed the CPET and DASI questionnaire once (validation sample). Patient characteristics are shown in Table 1. The derivation and validation samples were similar in terms of demographic, clinical, and laboratory characteristics. Direct-measured and DASI-estimated ̇o2peak values were similar in the two patient groups. Transplant patients were younger (55±10 years versus 60±14 years) and had higher eGFR (45.4±10 ml/min per 1.73 m2 versus 35.5±15 ml/min per 1.73 m2). Both direct-measured and DASI-estimated ̇o2peak values had good linear correlation with eGFR, with Pearson correlation coefficients of 0.42 (P<0.01) and 0.34 (P=0.02), respectively).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Study profile. Flow diagram of patient identification, enrollment, and distribution in the derivation and validation samples.

View this table:
  • View inline
  • View popup
Table 1.

Baseline patient characteristics

Analyses of Agreement

The results of unadjusted agreement analyses (concordance) are summarized in Table 2. DASI-estimated ̇o2peak tended to overestimate direct-measured ̇o2peak (average bias of 4.3 ml/kg per min; 95% limits of agreement, −5.3 to 14) with a CCC of 0.41 (95% CI, 0.24–0.60). Bias estimates were similar across categories of patient characteristics including levels of kidney function and diabetes. In adjusted analyses (mixed model including diabetes as fixed factor, subject/method as random factors, and eGFR to explain residual heteroscedasticity; not shown), the bias due to method (fixed effect) was 2.1 ml/kg per min (95% CI, 1.5–3 ml/kg per min).

View this table:
  • View inline
  • View popup
Table 2.

Bland–Altman analysis

A correction factor was derived from concordance analysis, on the basis of the major axis changes compared with the line of perfect agreement (Figure 2, top panels). When the correction factor was applied (corrected DASI-estimated ̇o2peak = DASI-estimated ̇o2peak × 0.638 + 3.056), the between-method agreement improved to a CCC of 0.62 (95% CI, 0.43–0.80). When the correction factor was applied in the validation cohort, a similar improvement in the CCC was observed (Table 2), although all estimates were less precise in this smaller sample (one measurement per participant) (Figure 2, bottom panels). All remaining calculations were performed applying the correction factor to the DASI-estimated ̇o2peak.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Agreement analysis plots. Direct-measured ̇o2peak in milliliters per kilogram per minute (y axis) over DASI-estimated ̇o2peak (x axis) on the derivation sample (top panels) and validation sample (bottom panels). Left panels refer to the uncorrected DASI-estimated ̇o2peak and right panels to the corrected DASI-estimated ̇o2peak. DASI, Duke Activity Status Index.

Variance Components

Table 3 summarizes the results of regression analyses. Adjusted analyses show that on average the study participants had direct-measured ̇o2peak values of 17 ml/kg per min (95% CI, 16–19 ml/kg per min). The only variable with a significant fixed effect was diabetes (̇o2peak values 3 ml/kg per min lower; 95% CI, −5.6 to −0.7). None of the other clinical characteristics or laboratory variables had significant fixed or random effects. However, residual variance was smaller in participants with eGFR <35 ml/min per 1.73 m2 (median) than in those with eGFR ≥35 ml/min per 1.73 m2 (P<0.01). It can be seen that the full model (model 2), relaxing the assumption of equal method reliability did not significantly improve the fit compared with the reduced model (model 1), indicating that test–retest reliability was similar.

View this table:
  • View inline
  • View popup
Table 3.

Regression analysis (linear mixed models)

Figure 3 shows the ICCs calculated from these regression models. The ICC estimates the between- and within-method reliability as the proportion of the total variance in the data due to patient and measurement methods. The ICC due to patient, intertest reliability, or validity of the DASI questionnaire was estimated at 53% in participants with eGFR between 35 and 59 ml/min per 1.73 m2 and at 60% in those with eGFR between 15 and 34 ml/min per 1.73 m2. Finally, despite tests being performed 6 months apart, the test–retest (intratest) reliability was similar across methods, again with better performance of both in participants with eGFR between 15 and 34 ml/min per 1.73 m2 (81%) than in those with greater eGFR (71%).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Intraclass correlation coefficients. (Left panel) The correlation (ICC) due to participants (between-test reliability) indicates that independent of the method used, there remains a considerable amount of variability in the data (i.e., the agreement of two measurements taken with different methods is between 50% and 60%). This residual variance is larger in participants with greater GFR (eGFR of 35–59 ml/min per 1.73 m2). (Right panel) Methods seem to be equally reliable. In fact, the intratest reliability (or consistency of the measures obtained using the same method in the same patient) is approximately 80% if eGFR is 15–34 ml/min per 1.73 m2 and 70% if eGFR is 35–59 ml/min per 1.73 m2. ICC, intraclass correlation coefficient; eGFR, estimated GFR. CPET, cardiopulmonary exercise test; DASI, Duke Activity Status Index.

Discussion

We conducted a reliability study of the DASI questionnaire (23) as a predictor of EC in CKD patients. The main findings of our study are as follows. First, DASI-estimated ̇o2peak values have a relatively high degree of agreement (53%–60%) with those measured with the reference standard CPET (validity). Second, both the DASI questionnaire and CPET are equally and highly reliable in CKD patients, with a test–retest reliability between 71% and 81%. Third, estimates of reliability vary by levels of kidney function, both being higher in participants with eGFR <35 ml/min per 1.73 m2. Our study has important implications for clinical practice and future research of EC in CKD.

Although formal reliability studies are lacking, the DASI questionnaire has been used in kidney research (2,28). One study indicates that DASI scores are lower in CKD patients than in participants with normal kidney function, and scores decrease as kidney function declines (12). The mean ̇o2peak in both the derivation and validation cohorts of this study was similar to previous studies (8,9). To our knowledge, this is the first study to examine the relationship between ̇o2peak values predicted from the DASI questionnaire and those measured with CPET. We found that in CKD patients DASI-estimated ̇o2peak tends to overestimate measured ̇o2peak by approximately 4.3 ml/kg per min (2.1 ml/kg per min in adjusted models). In our study, this translated into a coefficient of agreement of approximately 40%, which could be significantly improved to 60% by applying a correction factor. There are several reasons that may explain this amount of bias. First, although it is possible that the intermethod agreement has been overestimated in this small cohort, it is important to note that the agreement was even higher in the validation cohort (75%). In addition, the bias was smaller after adjusting for diabetes; it is possible that other unmeasured comorbid factors may contribute to the residual bias. Second, the equation to derive ̇o2peak from the DASI score was developed in cardiac patients and may not apply to the CKD population. The correlation between calculated and measured ̇o2peak was 0.58 in the original study (23) but was lower in other patient populations (26,33). Although our correction factor partly addressed this issue, the questionnaire items and their relative weights may be further modified in the presence of CKD. Third, and more importantly, the questionnaire tool may need to be revised because the weighting of each question may not reflect the same level of physical exertion as it did when the DASI questionnaire was first implemented, partly due to development of technology to assist household activities.

The second important finding of our study is the high test–retest reliability of the DASI questionnaire in CKD, similar to that of CPET. A test–retest CPET reliability of 98% has been reported in patients with ESRD when measures are taken 1 week apart (34). The lower reliability in our data (72%–82% depending on the severity of CKD) may be partly explained by the longer interval between the tests (6 months), during which true changes in physical capacity may have occurred. However, independent of the underlying mechanisms leading to these changes in the true ̇o2peak, both methods in our study were affected in the same way and resulted in being similarly reliable.

The third important finding of our study is the varying degree of reliability observed by level of kidney function. The agreement between direct-measured and DASI-estimated ̇o2peak was significantly greater when eGFR was <35 ml/min per 1.73 m2 (median). Patients with a lower eGFR may be a more homogeneous group in terms of EC than patients with more preserved eGFR. It is possible that in individuals with more severe CKD and lower EC (12), DASI scores tend to more closely reflect the relationship between perceived physical capacity and true ̇o2peak. Therefore, further research to determine the utility of the DASI questionnaire in patients with CKD should focus on participants with stage 4–5 CKD (eGFR <30 ml/min per 1.73 m2).

This study has several limitations. First, lack of randomization of the order of testing may have introduced systematic bias in the estimate of the intermethod agreement. However, the DASI questionnaire was always completed first to avoid the possibility that the cycle ergometer experience could influence the subjective responses to the questionnaire. Second, we maintained the scheduled follow-up appointments, resulting in a 6-month interval between repeated measures. Although it is likely that questionnaire response recall bias was eliminated, this long interval may have biased downward the estimates of reliability. Third, we powered the study to detect a bias of 5 ml/kg per min in the ̇o2peak between methods in clinically stable patients with CKD, but could not include follow-up data in the study design. All comparisons were made in this clinically stable and relatively healthy CKD population under the assumption that exercise testing is the reference standard of EC. However, data from a more heterogeneous patient population, including clinically unstable patients and long-term patient outcomes, are necessary to establish the utility of the DASI questionnaire in CKD.

In summary, our data show that the DASI questionnaire can be reliably used as a measure of EC in clinically stable patients with CKD. The DASI questionnaire has a relatively high agreement with ̇o2peak measured with CPET, especially if a correction factor is applied to the raw data. The high intratest reliability of the DASI questionnaire indicates its potential for use in clinical practice, especially in participants with stage 4–5 CKD. Larger prospective studies are needed to determine the prognostic value of this questionnaire and to assist the design of intervention studies to improve the EC of the growing CKD population.

Disclosures

None.

Acknowledgments

The authors thank all of the patients who participated in the study, as well as the Southern Alberta Renal Program, Alberta Transplant Program, and the Alberta Kidney Disease Network research staff who supported this study.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • This article contains supplemental material online at http://cjasn.asnjournals.org/lookup/suppl/doi:10.2215/CJN.07990811/-/DCSupplemental.

  • Received August 7, 2011.
  • Accepted December 9, 2011.
  • Copyright © 2012 by the American Society of Nephrology

References

  1. ↵
    1. Coresh J,
    2. Selvin E,
    3. Stevens LA,
    4. Manzi J,
    5. Kusek JW,
    6. Eggers P,
    7. Van Lente F,
    8. Levey AS
    : Prevalence of chronic kidney disease in the United States. JAMA 298: 2038–2047, 2007pmid:17986697
    OpenUrlCrossRefPubMed
  2. ↵
    1. Cook WL
    : The intersection of geriatrics and chronic kidney disease: Frailty and disability among older adults with kidney disease. Adv Chronic Kidney Dis 16: 420–429, 2009pmid:19801132
    OpenUrlCrossRefPubMed
  3. ↵
    1. American College of Sports Medicine
    : ACSM’s Guidelines for Exercise Testing and Prescription, Baltimore, Lippincott, Williams & Wilkins, 2009
  4. Goldstein RE: Exercise capacity. In: Clinical Methods: The History, Physical, and Laboratory Examinations, edited by Walker HK, Hall WD, Hurst JW, 3rd Ed., Boston, Butterworth Publishers, 1990
  5. ↵
    1. Johansen KL
    : Exercise and chronic kidney disease: Current recommendations. Sports Med 35: 485–499, 2005pmid:15974634
    OpenUrlCrossRefPubMed
  6. ↵
    1. Paterson DH,
    2. Cunningham DA,
    3. Koval JJ,
    4. St Croix CM
    : Aerobic fitness in a population of independently living men and women aged 55-86 years. Med Sci Sports Exerc 31: 1813–1820, 1999pmid:10613433
    OpenUrlCrossRefPubMed
  7. ↵
    1. Stathokostas L,
    2. Jacob-Johnson S,
    3. Petrella RJ,
    4. Paterson DH
    : Longitudinal changes in aerobic power in older men and women. J Appl Physiol 97: 781–789, 2004pmid:15047671
    OpenUrlCrossRefPubMed
  8. ↵
    Mustata S, Groeneveld S, Davidson W, Ford G, Kiland K, Manns B: Effects of exercise training on physical impairment, arterial stiffness and health-related quality of life in patients with chronic kidney disease: A pilot study. Int Urol Nephrol 43: 1133–1141, 2011
  9. ↵
    1. Padilla J,
    2. Krasnoff J,
    3. Da Silva M,
    4. Hsu CY,
    5. Frassetto L,
    6. Johansen KL,
    7. Painter P
    : Physical functioning in patients with chronic kidney disease. J Nephrol 21: 550–559, 2008pmid:18651545
    OpenUrlPubMed
  10. ↵
    1. Myers J,
    2. Prakash M,
    3. Froelicher V,
    4. Do D,
    5. Partington S,
    6. Atwood JE
    : Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 346: 793–801, 2002pmid:11893790
    OpenUrlCrossRefPubMed
  11. ↵
    1. O’Hare AM,
    2. Tawney K,
    3. Bacchetti P,
    4. Johansen KL
    : Decreased survival among sedentary patients undergoing dialysis: Results from the dialysis morbidity and mortality study wave 2. Am J Kidney Dis 41: 447–454, 2003pmid:12552509
    OpenUrlCrossRefPubMed
  12. ↵
    1. Kurella M,
    2. Ireland C,
    3. Hlatky MA,
    4. Shlipak MG,
    5. Yaffe K,
    6. Hulley SB,
    7. Chertow GM
    : Physical and sexual function in women with chronic kidney disease. Am J Kidney Dis 43: 868–876, 2004pmid:15112178
    OpenUrlCrossRefPubMed
  13. ↵
    1. Dalrymple LS,
    2. Katz R,
    3. Kestenbaum B,
    4. Shlipak MG,
    5. Sarnak MJ,
    6. Stehman-Breen C,
    7. Seliger S,
    8. Siscovick D,
    9. Newman AB,
    10. Fried L
    : Chronic kidney disease and the risk of end-stage renal disease versus death. J Gen Intern Med 26: 379–385, 2011pmid:20853156
    OpenUrlCrossRefPubMed
    1. Foley RN,
    2. Parfrey PS,
    3. Sarnak MJ
    : Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32[Suppl 3]: S112–S119, 1998pmid:9820470
    OpenUrlCrossRefPubMed
  14. ↵
    1. Keith DS,
    2. Nichols GA,
    3. Gullion CM,
    4. Brown JB,
    5. Smith DH
    : Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164: 659–663, 2004pmid:15037495
    OpenUrlCrossRefPubMed
  15. ↵
    1. Sietsema KE,
    2. Amato A,
    3. Adler SG,
    4. Brass EP
    : Exercise capacity as a predictor of survival among ambulatory patients with end-stage renal disease. Kidney Int 65: 719–724, 2004pmid:14717947
    OpenUrlCrossRefPubMed
  16. ↵
    1. Bronas UG
    : Exercise training and reduction of cardiovascular disease risk factors in patients with chronic kidney disease. Adv Chronic Kidney Dis 16: 449–458, 2009pmid:19801135
    OpenUrlCrossRefPubMed
    1. Dickinson HO,
    2. Mason JM,
    3. Nicolson DJ,
    4. Campbell F,
    5. Beyer FR,
    6. Cook JV,
    7. Williams B,
    8. Ford GA
    : Lifestyle interventions to reduce raised blood pressure: A systematic review of randomized controlled trials. J Hypertens 24: 215–233, 2006pmid:16508562
    OpenUrlCrossRefPubMed
    1. Durstine JL,
    2. Grandjean PW,
    3. Davis PG,
    4. Ferguson MA,
    5. Alderson NL,
    6. DuBose KD
    : Blood lipid and lipoprotein adaptations to exercise: A quantitative analysis. Sports Med 31: 1033–1062, 2001pmid:11735685
    OpenUrlCrossRefPubMed
  17. ↵
    1. Sigal RJ,
    2. Kenny GP,
    3. Boulé NG,
    4. Wells GA,
    5. Prud’homme D,
    6. Fortier M,
    7. Reid RD,
    8. Tulloch H,
    9. Coyle D,
    10. Phillips P,
    11. Jennings A,
    12. Jaffey J
    : Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: A randomized trial. Ann Intern Med 147: 357–369, 2007pmid:17876019
    OpenUrlCrossRefPubMed
  18. ↵
    1. Fleg JL,
    2. Piña IL,
    3. Balady GJ,
    4. Chaitman BR,
    5. Fletcher B,
    6. Lavie C,
    7. Limacher MC,
    8. Stein RA,
    9. Williams M,
    10. Bazzarre T
    : Assessment of functional capacity in clinical and research applications: An advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association. Circulation 102: 1591–1597, 2000pmid:11004153
    OpenUrlFREE Full Text
  19. ↵
    1. Koufaki P,
    2. Kouidi E
    : Current best evidence recommendations on measurement and interpretation of physical function in patients with chronic kidney disease. Sports Med 40: 1055–1074, 2010pmid:21058751
    OpenUrlCrossRefPubMed
  20. ↵
    1. Hlatky MA,
    2. Boineau RE,
    3. Higginbotham MB,
    4. Lee KL,
    5. Mark DB,
    6. Califf RM,
    7. Cobb FR,
    8. Pryor DB
    : A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol 64: 651–654, 1989pmid:2782256
    OpenUrlCrossRefPubMed
  21. ↵
    1. Alonso J,
    2. Permanyer-Miralda G,
    3. Cascant P,
    4. Brotons C,
    5. Prieto L,
    6. Soler-Soler J
    : Measuring functional status of chronic coronary patients. Reliability, validity and responsiveness to clinical change of the reduced version of the Duke Activity Status Index (DASI). Eur Heart J 18: 414–419, 1997pmid:9076377
    OpenUrlCrossRefPubMed
    1. Arena R,
    2. Humphrey R,
    3. Peberdy MA
    : Using the Duke Activity Status Index in heart failure. J Cardiopulm Rehabil 22: 93–95, 2002pmid:11984206
    OpenUrlCrossRefPubMed
  22. ↵
    1. Carter R,
    2. Holiday DB,
    3. Grothues C,
    4. Nwasuruba C,
    5. Stocks J,
    6. Tiep B
    : Criterion validity of the Duke Activity Status Index for assessing functional capacity in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil 22: 298–308, 2002pmid:12202852
    OpenUrlCrossRefPubMed
  23. ↵
    1. Cook SA,
    2. MacLaughlin H,
    3. Macdougall IC
    : A structured weight management programme can achieve improved functional ability and significant weight loss in obese patients with chronic kidney disease. Nephrol Dial Transplant 23: 263–268, 2008pmid:17977872
    OpenUrlCrossRefPubMed
  24. ↵
    1. Nonoyama ML,
    2. Brooks D,
    3. Ponikvar A,
    4. Jassal SV,
    5. Kontos P,
    6. Devins GM,
    7. Spanjevic L,
    8. Heck C,
    9. Laprade J,
    10. Naglie G
    : Exercise program to enhance physical performance and quality of life of older hemodialysis patients: A feasibility study. Int Urol Nephrol 42: 1125–1130, 2010pmid:20213292
    OpenUrlCrossRefPubMed
  25. ↵
    1. Manns BJ,
    2. Mortis GP,
    3. Taub KJ,
    4. McLaughlin K,
    5. Donaldson C,
    6. Ghali WA
    : The Southern Alberta Renal Program database: A prototype for patient management and research initiatives. Clin Invest Med 24: 164–170, 2001pmid:11558850
    OpenUrlPubMed
  26. ↵
    1. Levey AS,
    2. Bosch JP,
    3. Lewis JB,
    4. Greene T,
    5. Rogers N,
    6. Roth D,
    7. Modification of Diet in Renal Disease Study Group
    : A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130: 461–470, 1999pmid:10075613
    OpenUrlCrossRefPubMed
  27. ↵
    1. Borg GA
    : Psychophysical bases of perceived exertion. Med Sci Sports Exerc 14: 377–381, 1982pmid:7154893
    OpenUrlCrossRefPubMed
  28. ↵
    Sophia Rabe-Hesketh AS: Multilevel and Longitudinal Modeling Using Stata, College Station, TX, Stata Press, 2008
  29. ↵
    1. Myers J,
    2. Zaheer N,
    3. Quaglietti S,
    4. Madhavan R,
    5. Froelicher V,
    6. Heidenreich P
    : Association of functional and health status measures in heart failure. J Card Fail 12: 439–445, 2006pmid:16911910
    OpenUrlCrossRefPubMed
  30. ↵
    1. Koufaki P,
    2. Naish PF,
    3. Mercer TH
    : Reproducibility of exercise tolerance in patients with end-stage renal disease. Arch Phys Med Rehabil 82: 1421–1424, 2001pmid:11588748
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 7 (4)
Clinical Journal of the American Society of Nephrology
Vol. 7, Issue 4
April 06, 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
The Duke Activity Status Index in Patients with Chronic Kidney Disease: A Reliability Study
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Duke Activity Status Index in Patients with Chronic Kidney Disease: A Reliability Study
Pietro Ravani, Brett Kilb, Harman Bedi, Sharon Groeneveld, Serdar Yilmaz, Stefan Mustata, Alberta Kidney Disease Network
CJASN Apr 2012, 7 (4) 573-580; DOI: 10.2215/CJN.07990811

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
The Duke Activity Status Index in Patients with Chronic Kidney Disease: A Reliability Study
Pietro Ravani, Brett Kilb, Harman Bedi, Sharon Groeneveld, Serdar Yilmaz, Stefan Mustata, Alberta Kidney Disease Network
CJASN Apr 2012, 7 (4) 573-580; DOI: 10.2215/CJN.07990811
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Summary
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

Original Articles

  • Association of Polypharmacy with Kidney Disease Progression in Adults with CKD
  • The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function
  • Collectin11 and Complement Activation in IgA Nephropathy
Show more Original Articles

Chronic Kidney Disease

  • PCSK9 and Cardiovascular Disease in Individuals with Moderately Decreased Kidney Function
  • Apolipoprotein L1 High-Risk Genotypes and Albuminuria in Sub-Saharan African Populations
  • Treatment Decision Making for Older Kidney Patients during COVID-19
Show more Chronic Kidney Disease

Cited By...

  • Rationale and design of a cross-sectional study to investigate and describe the chronotype of patients with type 2 diabetes and the effect on glycaemic control: the CODEC study
  • Prognostic Value of Estimated Functional Capacity Incremental to Cardiac Biomarkers in Stable Cardiac Patients
  • Google Scholar

Similar Articles

Related Articles

  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire